We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+3.77%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$126M
AUM Growth
-$25.4M
Cap. Flow
-$29.2M
Cap. Flow %
-23.29%
Top 10 Hldgs %
74.71%
Holding
20
New
3
Increased
5
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.69M
2
UTHR icon
United Therapeutics
UTHR
+$7.67M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$6.5M
4
CVS icon
CVS Health
CVS
+$6.19M
5
SUPN icon
Supernus Pharmaceuticals
SUPN
+$1.93M

Top Sells

Rank Stock Value
1
VTRS icon
Viatris
VTRS
+$9.84M
2
COLL icon
Collegium Pharmaceutical
COLL
+$9.61M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$8.83M
4
ATRS
Antares Pharma, Inc.
ATRS
+$6.86M
5
CPRX
Catalyst Pharmaceutical
CPRX
+$5.84M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IRWD icon
1
Ironwood Pharmaceuticals
IRWD
$706M
$16.2M 12.91%
1,450,000
+615,000
+74% +$6.5M
SUPN icon
2
Supernus Pharmaceuticals
SUPN
$2.78B
$14M 11.13%
534,000
+69,000
+15% +$1.93M
ARAY icon
3
Accuray
ARAY
$33.7M
$9.78M 7.79%
1,975,000
+325,000
+20% +$1.68M
CHRS icon
4
Coherus Oncology
CHRS
$210M
$9.64M 7.68%
660,000
+60,000
+10% +$1.02M
BDSI
5
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$7.82M 6.23%
2,000,000
+425,000
+27% +$1.76M
UTHR icon
6
United Therapeutics
UTHR
$22.2B
$7.69M 6.13%
+46,000
New +$7.67M
VRTX icon
7
Vertex Pharmaceuticals
VRTX
$122B
$7.52M 5.99%
+35,000
New +$7.69M
ABBV icon
8
AbbVie
ABBV
$428B
$7.47M 5.95%
69,000
-18,000
-21% -$1.93M
UHS icon
9
Universal Health Services
UHS
$10.4B
$7.2M 5.74%
54,000
-14,000
-21% -$1.86M
COR icon
10
Cencora
COR
$61.3B
$6.49M 5.17%
55,000
-38,000
-41% -$4.11M
MCK icon
11
McKesson
MCK
$99.6B
$6.44M 5.13%
33,000
-20,000
-38% -$3.65M
CVS icon
12
CVS Health
CVS
$124B
$6.39M 5.09%
+85,000
New +$6.19M
CAH icon
13
Cardinal Health
CAH
$55.6B
$6.32M 5.03%
104,000
-65,000
-38% -$3.59M
BMY icon
14
Bristol-Myers Squibb
BMY
$130B
$6.31M 5.03%
100,000
-46,000
-32% -$2.86M
CI icon
15
Cigna
CI
$71.3B
$6.29M 5.01%
26,000
-21,000
-45% -$4.68M
COLL icon
16
Collegium Pharmaceutical
COLL
$1.02B
– –
-480,000
Closed -$9.61M
CPRX
17
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-1,750,000
Closed -$5.84M
TEVA icon
18
Teva Pharmaceuticals
TEVA
$40.3B
– –
-915,000
Closed -$8.83M
VTRS icon
19
Viatris
VTRS
$20B
– –
-525,000
Closed -$9.84M
ATRS
20
DELISTED
Antares Pharma, Inc.
ATRS
– –
-1,720,000
Closed -$6.86M

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return

HealthInvest Partners's Q1 2021 Portfolio in Review

As of Q1 2021, HealthInvest Partners held 20 positions worth $126M, down 17% from $151M the previous quarter. Its ten largest holdings account for 75% of the portfolio.

HealthInvest Partners withdrew a net $29.2M in Q1 2021, closing 5 positions and reducing 7 holdings. Its most notable exit was Viatris, an estimated $9.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, HealthInvest Partners opened a new position in Vertex Pharmaceuticals worth $7.52M.

  • HealthInvest Partners's largest Q1 2021 buy was Vertex Pharmaceuticals: 35,000 shares worth $7.52M.
  • HealthInvest Partners added most to Ironwood Pharmaceuticals in Q1 2021, an estimated $6.5M increase.
  • HealthInvest Partners's biggest Q1 2021 reduction was Cigna, cutting an estimated $4.68M.
  • HealthInvest Partners fully exited Viatris in Q1 2021, selling an estimated $9.84M.
  • HealthInvest Partners's ten largest holdings make up 75% of its $126M portfolio in Q1 2021.
  • HealthInvest Partners opened 3 new positions and closed 5 in Q1 2021.
  • HealthInvest Partners's portfolio value fell 17% quarter-over-quarter to $126M.

Based on HealthInvest Partners's 13F filing for Q1 2021, filed 30 Apr 2021.